Utz Brands, Inc. Form 8-K Summary
Business Context and Reporting Period
Utz Brands, Inc. filed a Form 8-K dated December 9, 2021, under Item 5.02 to report the appointment of a new independent director and changes to the director compensation program. The filing does not report operating results for a fiscal period.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating-financial metrics. No financial statements were included.
Material Changes
- Effective January 3, 2022, the Board will increase from 10 to 11 members.
- Pamela Stewart was appointed as an independent director and will serve on the Compensation Committee.
- Ms. Stewart will participate in the standard non-employee director compensation program, including an annual cash retainer of $75,000 and an annual equity retainer valued at $125,000 in restricted stock units, prorated in her first year.
- The Compensation Committee amended the director compensation program to provide the Board chair with an annual cash retainer of $90,000.
- Roger Deromedi and Jason Giordano waived director compensation for fiscal years 2020 and 2021; beginning in fiscal year 2022, both are expected to receive cash and equity compensation under the program.
Management Commentary, Outlook, and Risks
Ms. Stewart is President of West Zone Operations for The Coca-Cola Company’s North America Operating Unit and has more than 20 years of experience at Coca-Cola across finance, revenue growth management, sales, operations, and general management.
The filing contains no earnings guidance, business outlook, material risk updates, contingencies, or unusual operating items.
Important Facts to Verify
- Confirm Pamela Stewart’s effective appointment date of January 3, 2022, and her independent-director and Compensation Committee status.
- Review the attached December 9, 2021 press release for any additional appointment-related details.
- Verify implementation of the $90,000 annual cash retainer for the Board chair and the resumption of compensation for Deromedi and Giordano in fiscal 2022.
- Consult the company’s proxy statement or subsequent filings for the complete director compensation terms and any later changes.